# Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy

> **NCT07493395** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University Hospital, Montpellier** · enrollment: 6 (estimated)

## Conditions studied

- Scleroderma, Systemic

## Interventions

- **BIOLOGICAL:** CD19 CAR T Arm

## Key facts

- **NCT ID:** NCT07493395
- **Lead sponsor:** University Hospital, Montpellier
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2026-04-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07493395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07493395, "Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07493395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*